Ontology highlight
ABSTRACT:
SUBMITTER: Jeong SW
PROVIDER: S-EPMC7643594 | biostudies-literature | 2020 Oct
REPOSITORIES: biostudies-literature
Diabetes & metabolism journal 20201021 5
The worldwide prevalence of non-alcoholic fatty liver disease is around 25%, and that of nonalcoholic steatohepatitis (NASH) ranges from 1.5% to 6.45%. Patients with NASH, especially those with fibrosis, are at higher risk for adverse outcomes such as cirrhosis and liver-related mortality. Although vitamin E, pioglitazone, and liraglutide improved liver histology in randomized trials, there are currently no Food and Drug Administration-approved drugs for NASH. Five pharmacologic agents-obetichol ...[more]